BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 3478540)

  • 1. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
    Paciucci PA; Dutcher JP; Cuttner J; Strauman JJ; Wiernik PH; Holland JF
    Leukemia; 1987 Jul; 1(7):565-7. PubMed ID: 3478540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F; Catovsky D; Slocombe G; Newland AC; Marcus RE; Goldman JM; Galton DA
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Am J Hematol; 1990 Sep; 35(1):22-5. PubMed ID: 2202204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
    MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
    Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I; Akin U; Ismet A; Meral B; Hamdi A; Haluk K
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
    Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
    Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia.
    Amadori S; Meloni G; Petti MC; Papa G; Miniero R; Mandelli F
    Leukemia; 1989 Feb; 3(2):112-4. PubMed ID: 2911204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
    Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.